Cargando…
Clinical Efficacy of Huangkui Capsule plus Methylprednisolone in the Treatment of Nephropathy and the Effect on Urinary Protein and Serum Inflammatory Factors in Patients
OBJECTIVE: The study aimed to assess the clinical efficacy of Huangkui capsule plus methylprednisolone in the treatment of nephropathy and the effect on urinary protein and serum inflammatory factors in patients. METHODS: Between June 2017 and July 2020, 90 patients with nephropathy admitted to our...
Autores principales: | Wan, Weibo, Zhou, Jingjing, Lu, Rong, Wang, Chaoyang, Hu, Shuli, Liu, Mei, Xiong, Rong, Kuang, Jing, Fan, Xuepeng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279028/ https://www.ncbi.nlm.nih.gov/pubmed/35845574 http://dx.doi.org/10.1155/2022/6232264 |
Ejemplares similares
-
Retracted: Clinical Efficacy of Huangkui Capsule plus Methylprednisolone in the Treatment of Nephropathy and the Effect on Urinary Protein and Serum Inflammatory Factors in Patients
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023) -
Clinical Efficacy of Huangkui Capsule Plus Methylprednisolone for Immunoglobulin A Nephropathy and Its Effect on Renal Function and Serum Inflammatory Factors
por: Yuan, Lili, et al.
Publicado: (2023) -
Efficacy and safety of Huangkui capsule for diabetic nephropathy: A protocol for systematic review and meta-analysis
por: An, Wenrong, et al.
Publicado: (2021) -
Network pharmacology and molecular docking predictions of the active compounds and mechanism of action of Huangkui capsule for the treatment of idiopathic membranous nephropathy
por: Cai, Meng, et al.
Publicado: (2023) -
Huangkui Capsule in Combination with Leflunomide Improves Immunoglobulin A Nephropathy by Inhibiting the TGF-β1/Smad3 Signaling Pathway
por: Pei, Shuwen, et al.
Publicado: (2021)